BioSpace News Archive

Gb Sciences, Inc. describes their progress towards achieving significant milestones in their drug development pipeline in an article published in the journal Pharma’s Almanac.

Indaptus Therapeutics, Inc. announced that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference.

Biosense Webster, Inc., part of Johnson & Johnson MedTech‡, today announced the release of the OCTARAY™ Mapping Catheter with TRUEref™ Technology powered by the CARTO™ 3 Version 7 System.

Hovione, the leader in spray drying and particle engineering, announced that it has expanded its continuous manufacturing offering and services.

Alira Health, a patient-centric, global health care advisory, clinical research and technology company, announced the acquisition of Artisan Healthcare Consulting, a US-based consulting firm that provides strategic insights to healthcare companies.

BrainChip Holdings Ltd, the world’s first commercial producer of neuromorphic AI IP, announced that Chris Stevens has joined as Vice President of Worldwide Sales to lead and expand BrainChip sales.

Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that it has been selected to present at the 7th annual MicroCap Leadership Summit on Friday, September 16th, 2022.

CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, announced the completion of the 100th surgical procedure using the CurvaFix® IM Implant to repair a pelvic fragility fracture for a geriatric patient at University Hospital at the University of Missouri in Columbia, Mo.

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today they signed an agreement with Cellvera Global Holdings LLC (“Cellvera”), for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.

Patients Choice Laboratories announced that it has been awarded accreditation from the College of American Pathologists based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.